7 recruiting, 2 not yet recruiting. 4 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 2 | Not yet recruiting 2 |
Follow UBT251: new trials by email Literature Review of UBT251 trials Research Report on UBT251
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UBT251 Injection Phase Ⅲ Study (OSA-PAP) UBT251, Placebo - Obstructive Sleep Apnea, Obesity | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | 2026-10-10 | 2026-09-08 |
| UBT251 Injection Phase Ⅲ Study (OSA-NPAP) UBT251, Placebo - Obstructive Sleep Apnea, Obesity | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | 2026-09-18 | 2026-08-25 |
| A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant UBT251, Oral contraceptive, Acetaminophen - Overweight, Obesity | Phase 1 | Recruiting | Novo Nordisk A/S | 40 | 2026-07-17 | 2026-08-25 |
| A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight UBT251, Cocktail (Warfarin/Caffeine/Midazolam) - Obesity, Overweight | Phase 1 | Recruiting | Novo Nordisk A/S | 44 | 2026-07-15 | 2026-08-18 |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes UBT251, UBT251 Placebo, Semaglutide - Diabetes Mellitus, Type 2 | Phase 2 | Recruiting | Novo Nordisk A/S | 300 | 2026-06-22 | 2026-10-07 |
| Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity UBT251, Metformin hydrochloride, Warfarin Sodium - Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics | Phase 1 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 48 | 2026-05-27 | 2026-08-25 |
| A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity UBT251, Placebo - Overweight, Obesity | Phase 2 | Recruiting | Novo Nordisk A/S | 333 | 2026-02-02 | 2026-04-21 |
| A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) UBT251, Placebo - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 156 | 2025-09-30 | 2025-11-20 |
| UBT251 Injection Phase II Clinical Study (CKD) UBT251 - Obesity &Amp; Overweight, Chronic Kidney Disease | Phase 2 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 180 | 2025-09-01 | 2025-11-25 |
Obesity (7) · Overweight (5) · Sleep Apnea, Obstructive (2) · Diabetes Mellitus, Type 2 (1) · Renal Insufficiency, Chronic (1)
The United Bio-Technology (Hengqin) Co., Ltd. (5) · Novo Nordisk A/S (4)
China (3) · United States (3) · Canada (2) · Australia (1) · Germany (1) · Hungary (1) · Poland (1) · Romania (1) · Slovakia (1) · South Korea (1) · Spain (1)